Publications by authors named "Sridharan Rajgopal"
Int Immunopharmacol
May 2013
Article Synopsis
- The study investigates the selective inhibition of HDAC6 using Tubastatin, which shows promise in treating autoimmune and inflammatory diseases by modulating inflammatory cell functions.
- Tubastatin effectively reduces pro-inflammatory cytokines TNF-α and IL-6 in macrophage models, demonstrating its potential as a therapeutic agent with minimal toxicity.
- In animal models of inflammation and arthritis, Tubastatin significantly decreases disease symptoms and inflammatory markers, indicating its effectiveness compared to traditional treatments like dexamethasone.
